

## RESEARCH ARTICLE

## Role of hydrogen sulfide in sulfur dioxide production and vascular regulation

Chufan Sun<sup>1</sup>, Wen Yu<sup>2</sup>, Boyang Lv<sup>1</sup>, Yanan Zhang<sup>1</sup>, Shuxu Du<sup>3</sup>, Heng Zhang<sup>4</sup>, Junbao Du<sup>1,5</sup>, Hongfang Jin<sup>1</sup>, Yan Sun<sup>1\*</sup>, Yaqian Huang<sup>1\*</sup>

**1** Department of Pediatrics, Peking University First Hospital, Beijing, China, **2** Department of Cardiology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China, **3** Department of Pediatrics, Beijing Shijitan Hospital, Capital Medical University, Beijing, China, **4** Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China, **5** Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China

☞ These authors contributed equally to this work.

\* [yaqianhuang@126.com](mailto:yaqianhuang@126.com) (YH); [sunyan2007bjmu@163.com](mailto:sunyan2007bjmu@163.com) (YS)



## OPEN ACCESS

**Citation:** Sun C, Yu W, Lv B, Zhang Y, Du S, Zhang H, et al. (2022) Role of hydrogen sulfide in sulfur dioxide production and vascular regulation. PLoS ONE 17(3): e0264891. <https://doi.org/10.1371/journal.pone.0264891>

**Editor:** Jaap A. Joles, University Medical Center Utrecht, NETHERLANDS

**Received:** August 16, 2021

**Accepted:** February 19, 2022

**Published:** March 17, 2022

**Copyright:** © 2022 Sun et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper.

**Funding:** This work was funded by the grants from National Natural Science Foundation of China (81770422 to Yaqian Huang, 82070445 to Yaqian Huang, 81770278 to Junbao Du, 81970424 to Junbao Du, and 81921001 to Junbao Du) (<http://www.nsf.gov.cn/>), Beijing Natural Science Foundation (7191012 to Hongfang Jin) (<http://kw.beijing.gov.cn/>), Special fund for youth clinical research of Peking University First Hospital (2019CR20 to Yan Sun). The funders had no role in

## Abstract

Both hydrogen sulfide (H<sub>2</sub>S) and sulfur dioxide (SO<sub>2</sub>) are produced endogenously from the mammalian metabolic pathway of sulfur-containing amino acids and play important roles in several vascular diseases. However, their interaction during the control of vascular function has not been fully clear. Here, we investigated the potential role of H<sub>2</sub>S in SO<sub>2</sub> production and vascular regulation *in vivo* and *in vitro*. Wistar rats were divided into the vehicle, SO<sub>2</sub>, DL-propargylglycine (PPG) + SO<sub>2</sub>, β-cyano-L-alanine (BCA) + SO<sub>2</sub> and sodium hydrosulfide (NaHS) + SO<sub>2</sub> groups. SO<sub>2</sub> donor was administered with or without pre-administration of PPG, BCA or NaHS for 30 min after blood pressure was stabilized for 1 h, and then, the change in blood pressure was detected by catheterization via the common carotid artery. Rat plasma SO<sub>2</sub> and H<sub>2</sub>S concentrations were measured by high performance liquid chromatography and sensitive sulfur electrode, respectively. The isolated aortic rings were prepared for the measurement of changes in vasorelaxation stimulated by SO<sub>2</sub> after PPG, BCA or NaHS pre-incubation. Results showed that the intravenous injection of SO<sub>2</sub> donors caused transient hypotension in rats compared with vehicle group. After PPG or BCA pretreatment, the plasma H<sub>2</sub>S content decreased but the SO<sub>2</sub> content increased markedly, and the hypotensive effect of SO<sub>2</sub> was significantly enhanced. Conversely, NaHS pretreatment upregulated the plasma H<sub>2</sub>S content but reduced SO<sub>2</sub> content, and attenuated the hypotensive effect of SO<sub>2</sub>. After PPG or BCA pre-incubation, the vasorelaxation response to SO<sub>2</sub> was enhanced significantly. While NaHS pre-administration weakened the SO<sub>2</sub>-induced relaxation in aortic rings. In conclusion, our *in vivo* and *in vitro* data indicate that H<sub>2</sub>S negatively controls the plasma content of SO<sub>2</sub> and the vasorelaxant effect under physiological conditions.

## Introduction

Sulfur dioxide (SO<sub>2</sub>) was previously considered a toxic gas, but it has been proven that it can be endogenously produced from the metabolism of sulfur-containing amino acids, with L-

study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

cysteine as a substrate and catalyzed by aspartate aminotransferase (AAT) [1,2]. Our previous studies revealed the existence of the SO<sub>2</sub>/AAT pathway in arteries and its vasodilator function [3]. Studies have also confirmed its effect on vascular function [4]. Supplementation with SO<sub>2</sub> donors could protect against various cardiovascular diseases. Emerging evidence indicated that endogenous SO<sub>2</sub> is a new gasotransmitter involved in cardiovascular regulation. Interestingly, in a variety of pathological models, including atherosclerosis [5], pulmonary hypertension [6], and myocardial ischemia-reperfusion injury [7], SO<sub>2</sub> was found to affect the production of another gasotransmitter, hydrogen sulfide (H<sub>2</sub>S). However, the interaction between H<sub>2</sub>S and SO<sub>2</sub> under physiological conditions is largely unknown.

L-Cysteine is used as a substrate to produce the endogenous H<sub>2</sub>S in the cardiovascular system through cystathionine- $\gamma$ -lyase (CSE) [8–11]. Endogenous H<sub>2</sub>S not only has physiological functions, such as vasorelaxation, but also has pathophysiological effects, including the inhibition of hypertension [10,12–17]. Recently, we showed that in a monocrotaline-induced pulmonary hypertensive rat model, the H<sub>2</sub>S pathway in pulmonary artery endothelial cells is damaged, which reduces the sulfhydration of AAT, thus enhancing AAT activity and increasing SO<sub>2</sub> production [18]. However, it is still unclear whether H<sub>2</sub>S affects the SO<sub>2</sub> pathway under physiological conditions.

As mentioned above, the importance of H<sub>2</sub>S and SO<sub>2</sub> for the modulation of blood pressure and arterial tension has been gradually revealed, but their interaction in the control of blood pressure and vascular function has not been clear. Thus, our research aimed at exploring the possible role of H<sub>2</sub>S in SO<sub>2</sub> production and vascular regulation under physiological conditions.

## Materials and methods

### Reagents

Acetylcholine chloride (ACH) and phenylephrine (PE) were from Beijing Chemical Reagent Company and Tianjin Amino Acid Company in China, respectively. Sodium sulfite and sodium bisulfite (Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub>, the SO<sub>2</sub> donor), DL-propargylglycine (PPG, a selective CSE inhibitor),  $\beta$ -cyano-L-alanine (BCA, another CSE inhibitor), and sodium hydrosulfide (NaHS, the H<sub>2</sub>S donor) were from Sigma, USA. Since SO<sub>2</sub>, HSO<sub>3</sub><sup>-</sup> and HSO<sub>3</sub><sup>2-</sup> can be transformed into each other in biological system [1], NaHSO<sub>3</sub>/Na<sub>2</sub>SO<sub>3</sub> was used as the SO<sub>2</sub> donor (S1 Fig). NaHSO<sub>3</sub> and Na<sub>2</sub>SO<sub>3</sub> were dissolved in deionized water at a molar ratio of 1:3. The fresh SO<sub>2</sub> donor stock solution was then diluted with bath solution to obtain a series of working solutions with different concentrations. The handling and properties of NaHS were given in a brochure by Stauffer (1974). It is produced by the absorption of H<sub>2</sub>S in sodium hydroxide and shipped as a 45% solution with a specific gravity of 1.303 and a pH of 10.4 [19]. NaHS powder was rapidly dissolved in normal saline (0.9%) to obtain the desired concentration of stock solutions (pH 7.4) which was immediately injected intravenously into the right external iliac vein of rats or added into the organ bath solution of aortic rings (37°C). Previous study showed that given a physiological pH around 7.4 and temperature of 37°C, NaHS solution will yield about one-third of the undissociated H<sub>2</sub>S gas and the other two-thirds remain as HS<sup>-</sup> [20]. The composition of the Krebs' solution with pH 7.2–7.4 was as follows: NaCl (120 mmol/L), KCl (5.5 mmol/L), NaHCO<sub>3</sub> (20 mmol/L), CaCl<sub>2</sub> (2.5 mmol/L), MgCl<sub>2</sub>·6H<sub>2</sub>O (1.2 mmol/L), NaH<sub>2</sub>PO<sub>4</sub> (1.2 mmol/L), EDTA-Na<sub>2</sub> (0.03 mmol/L) and glucose (10 mmol/L).

### Animal experiment

Animal care and operation procedures were carried out strictly in accordance with the Animal Management Rule of the Ministry of Health of the People's Republic of China (Documentation

55, 2001). The protocol was approved by the Animal Care Committee of Peking University First Hospital (Protocol Number: J202044) and conformed to the ARRIVE guidelines (<https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3000411>). Forty male Wistar rats (body weight, 200±5 g) were purchased from the Experimental Animal Center, Peking University Health Science Center (Beijing, China). They were housed at a constant temperature of 25°C under a 12-h light-dark cycle and maintained on *ad libitum* food and water. Rats were monitored twice daily for health status and husbandry conditions. In the health monitoring, we closely observed the food consumption, water intake, body weight and general assessment of rat activity, panting, and fur condition of the rats. During the whole experiment, intraperitoneal injection of sodium pentobarbital (45 mg/kg) was used for anesthesia and supplemented with an additional dose of 10 mg/kg. All efforts were made to minimize suffering. They were randomly assigned to five groups (n = 8 each) as follows: (1) vehicle group where the rats were intravenously injected with the equal volume of physiological saline; (2) SO<sub>2</sub> group where the rats were intravenously injected with Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (40 μmol/kg, pH 7.4); (3) PPG + SO<sub>2</sub> group where the rats were given PPG (30 mg/kg) intravenously and then Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (40 μmol/kg) 30 min later; (4) BCA + SO<sub>2</sub> group where the rats were given BCA (50 mg/kg) intravenously and then Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (40 μmol/kg) 30 min later; (5) NaHS + SO<sub>2</sub> group where the rats were given NaHS (56 μmol/kg) [21,22] intravenously and then Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (40 μmol/kg) [23,24] 30 min later. PPG (30 mg/ml), BCA (50 mg/ml), NaHS (56 μmol/ml) or Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (40 μmol/ml) in a final volume of 200 μl was injected intravenously into the femoral vein within a minute. After the experiment, the rats were euthanized with intravenous injection of an overdose of sodium pentobarbital.

### Preparation of rat model and measurement of blood pressure

Two polyethylene catheters were inserted into the left common carotid artery (LCCA) and the right external iliac vein. The mean blood pressure (MBP) was measured via the LCCA, and the extracorporeal end of the catheter was connected to a pressure sensor and PowerLab Software for recording blood pressure and respiratory conditions. (BL-410, Chengdu TME Technology, China) [25]. The extracorporeal end of catheter in the right external iliac vein was connected to a 5 ml syringe for intravenous bolus injection of chemicals and collection of venous blood samples.

### Measurement of plasma H<sub>2</sub>S and SO<sub>2</sub> content

Plasma sulfide levels were detected using a free radical analyzer TBR4100 with an H<sub>2</sub>S-selective sensor (World Precision Instruments, China) to reflect H<sub>2</sub>S content as previously described [26]. Briefly, the electrode was activated in deionized water for more than 2 h. The measured item of this analyzer was set to millivolt. The sensitive sulfur electrode was immersed into 1 mL of sample, so was the reference electrode. And the millivolt value was recorded after the reading was stable. Plasma SO<sub>2</sub> concentration was detected by HPLC [3]. Briefly, the sulfite in the sample was reduced to a sulfhydryl compound by the addition of sodium borohydride. Then, it was combined with monobromobimane, and perchloric acid was added to remove the protein in the sample, which was neutralized by use of Tris-HCl (pH 3.0). Small sulfhydryl molecules were separated from other fractions through chromatographic analysis and determined with a fluorescence detector.

### AAT activity assay

Purified AAT protein (Roche Diagnostics, Mannheim, Germany) was incubated with or without PPG (100 μmol/L) for 30 min at 37°C in PBS buffer. After incubation, the activity of AAT

was measured using AAT Assay Kit (Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer's instructions and was expressed in Carmen's Unit.

### Preparation of rat aortic rings

Thoracic aortas were rapidly isolated from anesthetized male Wistar rats ( $n = 8$  per group) with the removal of adherent adipose and connective tissue. Each aorta was cut into 3–4 aortic rings of 3 mm in length and immersed in Krebs' buffer at 4°C. During the whole process, artificially overstretching blood vessels was avoided to maintain their activity.

### Measurement of the rat aortic contractility

The aortic rings were immersed into organ baths containing oxygenated Krebs' buffer at 37.5°C, fixed, and connected with a tension sensor. The latter was then connected with a multi-channel physiological recorder to record the tension value and display them through PowerLab software [3]. The rings were first stretched to a tension of 1 g (international unit  $9.8 \times 10^{-3}$  Newton) and equilibrated for 60 min. During this period, the incubation solution was replaced every 15 min. After the tension stabilized, the aortic rings were ready for testing.

To confirm the vascular reactivity, the aortic rings were first treated with PE (1  $\mu\text{mol/L}$ ) for contraction. After reaching equilibrium, they were treated with ACH (1  $\mu\text{mol/L}$ ) for relaxation. Those with good reactivity were used for the following procedures. After the peak of relaxation, the rings were rinsed with Krebs' buffer three times. When the tension of the rings became stable again and returned to the initial level, the aortic rings were incubated with vehicle, PPG (100  $\mu\text{mol/L}$ ), BCA (100  $\mu\text{mol/L}$ ) or NaHS (50  $\mu\text{mol/L}$ ) for 10 min, and then PE (3  $\mu\text{mol/L}$ ) was added to make the rings in precontraction state. After that, a dose-response to Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (50–1000  $\mu\text{mol/L}$ ) in aortic rings was detected. Relaxation was expressed as the percentage reduction of the maximum precontraction achieved by PE.

In the experiment of measuring vasoconstriction response, the rings were first stretched to a tension of 1 g, equilibrated for 20 min, and then contracted with 60 mmol/L KCl for 15 min to test its contractility. After rinsing with Krebs' buffer three times and the tension stabilized, the rings were incubated with Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (1 mmol/L) or PPG (100  $\mu\text{mol/L}$ ) plus Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub>, and subsequently a dose-response to PE was detected. Contraction was expressed as the percentage of its peak contraction with 60 mmol/L KCl.

### Measurement of plasma nitric oxide (NO) content

The plasma NO content was detected using the NO assay kit (Applygen, Beijing, China). Briefly, 50  $\mu\text{L}$  of standard and plasma sample were added to a 96-well plate and 50  $\mu\text{L}$  of Griess R1 solution was then added to these wells and incubated at 37°C for 2 h. After that, 50  $\mu\text{L}$  of Griess R2 solution was added and incubated in dark at 37°C for 5 min, and the absorbance values were measured at 540 nm.

### Western blot

The aortic tissues were homogenated with lysis buffer containing protease inhibitors and phosphatase inhibitors. Then, the supernatants were obtained by centrifuging at 12000 g for 20 min. An equal amount of aortic protein was isolated by SDS-PAGE electrophoresis and transferred to nitrocellulose (NC) membranes. The NC membranes were blocked using 5% skim milk and then incubated with heme oxygenase (HO)-1 antibody (diluted 1:1000, Enzo Life Sciences, Farmingdale, NY, USA), HO-2 antibody (diluted 1:1000, Enzo Life Sciences), endothelial NO synthase (eNOS) antibody (diluted 1:1000, Cell Signaling Technology, Danvers, MA,

USA), and  $\beta$ -tubulin (diluted 1:5000, Beyotime Biotechnology, Beijing, China) overnight, respectively. After that, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Sigma-Aldrich Corporation, St Louis, MO, USA). The bands were detected with a chemiluminescence detection system (ProteinSimple, San Francisco, CA, USA).

## Statistics

SPSS 15.0 (SPSS, Chicago, IL, USA) was used for statistical analysis. Data are expressed as the mean  $\pm$  SEM. A Student's t-test was performed to compare differences between two groups. Paired-sample t-test was performed to compare the changes of plasma H<sub>2</sub>S and SO<sub>2</sub> contents in the rats before and after treatment. One-way ANOVA followed by least significant difference (LSD) test was performed to compare differences among multiple groups. P values less than 0.05 were considered significant.

## Results

### H<sub>2</sub>S inhibits the plasma levels of SO<sub>2</sub> *in vivo*

To investigate the effect of H<sub>2</sub>S on SO<sub>2</sub> level *in vivo*, the rats were intravenously injected with PPG, BCA or NaHS to downregulate or upregulate H<sub>2</sub>S level. As shown in Table 1, after intravenous injection of PPG (30 mg/kg), the rat plasma H<sub>2</sub>S concentration was decreased significantly (from 20.22  $\pm$  0.31  $\mu$ mol/L to 11.65  $\pm$  0.47  $\mu$ mol/L), whereas the plasma SO<sub>2</sub> content was increased notably (from 15.33  $\pm$  0.72  $\mu$ mol/L to 21.55  $\pm$  2.41  $\mu$ mol/L). In rats injected with BCA, another CSE inhibitor, we observed similar findings as in PPG-treated rats. Conversely, rats injected with NaHS to increase plasma H<sub>2</sub>S content (from 20.60  $\pm$  0.40  $\mu$ mol/L to 34.75  $\pm$  1.47  $\mu$ mol/L) exhibited a reduced plasma SO<sub>2</sub> content (from 15.16  $\pm$  0.65  $\mu$ mol/L to 12.75  $\pm$  1.12  $\mu$ mol/L). To explore whether PPG had any direct effect on SO<sub>2</sub> production, the purified SO<sub>2</sub> synthase AAT protein was treated with or without PPG in PBS buffer. The results showed that there was no difference in the activity of the purified AAT protein between the control group and the PPG group (Fig 1), implying that PPG had no direct effect on the SO<sub>2</sub> production. These data suggest that H<sub>2</sub>S negatively regulates the plasma levels of SO<sub>2</sub>.

### H<sub>2</sub>S attenuated the hypotensive effect of SO<sub>2</sub> *in vivo*

To explore the significance of SO<sub>2</sub> level inhibition by H<sub>2</sub>S, the rats were intravenously injected with physiological saline, PPG, BCA or NaHS for 30 minutes, followed by SO<sub>2</sub> derivatives (Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub>) injection, and the changes of their blood pressure were monitored in real time (Fig 2A). Injection of physiological saline did not affect MBP of rats in vehicle group (Fig 2B). However, the MBP of rats in the SO<sub>2</sub> group dropped by 22.55% within 1.5 minutes

**Table 1. Plasma contents of H<sub>2</sub>S and SO<sub>2</sub> in rats before and after treatment with PPG, BCA or NaHS.**


Groups	H <sub>2</sub> S content ( $\mu$ mol/L)			SO <sub>2</sub> content ( $\mu$ mol/L)	
	0 min	5 min	30 min	0 min	30 min
PPG	20.22 $\pm$ 0.31	–	11.65 $\pm$ 0.47*	15.33 $\pm$ 0.72	21.55 $\pm$ 2.41 <sup>#</sup>
BCA	20.63 $\pm$ 0.34	–	11.00 $\pm$ 0.83*	12.48 $\pm$ 0.30	20.58 $\pm$ 1.52 <sup>#</sup>
NaHS	20.60 $\pm$ 0.40	34.75 $\pm$ 1.47*	20.94 $\pm$ 0.31	15.16 $\pm$ 0.65	12.75 $\pm$ 1.12 <sup>#</sup>

Data expressed as mean  $\pm$  SEM; n = 8 in each group; paired-sample t-test

\*P < 0.05 compared with the plasma H<sub>2</sub>S content of rats before treatment in the corresponding group

<sup>#</sup>P < 0.05 compared with the plasma SO<sub>2</sub> content of rats before treatment in the corresponding group. PPG, DL-propargylglycine; BCA,  $\beta$ -cyano-L-alanine; NaHS, sodium hydrosulfide.


<https://doi.org/10.1371/journal.pone.0264891.t001>



**Fig 1. PPG had no direct effect on AAT activity.** Purified AAT protein was incubated with or without PPG (100  $\mu$ mol/L) for 30 min at 37°C. Data are presented as mean  $\pm$  SEM; n = 9 in each group; Student's t-test; ns, not significant.

<https://doi.org/10.1371/journal.pone.0264891.g001>

after the intravenous injection of SO<sub>2</sub> derivatives; then, the MBP began to rise, and returned to the basal level 10 minutes after injection of SO<sub>2</sub> derivatives (Fig 2B). The rat MBP in the SO<sub>2</sub> group was significantly lower than that in the vehicle group within 1.5 minutes after the injection of SO<sub>2</sub> derivatives (Fig 2C). In the PPG+SO<sub>2</sub> group, there was no significant difference in MBP between the baseline and 30 minutes after administration of PPG; the MBP dropped by 32.19% within 1.5 min after SO<sub>2</sub> derivatives injection; then it began to rise, and returned to baseline 10 minutes after SO<sub>2</sub> derivatives injection (Fig 2B). The decrease in MBP of the PPG +SO<sub>2</sub> group was markedly greater than that of the SO<sub>2</sub> group within 1.5 minutes after SO<sub>2</sub> derivatives injection (Fig 2C). Similarly, the administration of rats with BCA, another CSE inhibitor, also exacerbated the hypotensive effect of SO<sub>2</sub>. The MBP was significantly decreased




**Fig 2. H<sub>2</sub>S inhibited the hypotension induced by SO<sub>2</sub> *in vivo*.** (A) Schematic diagram of strategies to explore the influence of the interaction of H<sub>2</sub>S and SO<sub>2</sub> on blood pressure regulation. Rats were intravenously injected with PPG (30 mg/kg), BCA (50 mg/kg), NaHS (56 μmol/kg) or equal volume of physiological saline. After 30 minutes, the rats were given an intravenous injection of Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (40 μmol/kg) or equal volume of saline, and then their blood pressure was continuously monitored for 30 minutes. Mean blood pressure (MBP) of rats was analyzed at different time points. (B) Changes in MBP of rats in each group at different time points. Data are mean±SEM; n = 8 in each group. (C) Comparison of the drop in MBP of rats in each group after administration of Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> for 1.5 minutes. Data are presented as mean±SEM; n = 8 in each group; One-way ANOVA followed by LSD post hoc test; \*P<0.05 compared with vehicle group; #P<0.05 compared with SO<sub>2</sub> group.

<https://doi.org/10.1371/journal.pone.0264891.g002>

within 1 minute after H<sub>2</sub>S donor NaHS injection (S2 Fig) and then returned to the basal level within 30 minutes (Fig 2B). Although pretreatment of rats with NaHS caused a decrease in MBP within 1–3 minutes after the injection of SO<sub>2</sub> derivatives, the decrease in MBP was significantly smaller than that of the SO<sub>2</sub> group (Fig 2). These data suggest that H<sub>2</sub>S could inhibit the hypotensive effect of SO<sub>2</sub>.

### H<sub>2</sub>S negatively controls the vasorelaxant effect of SO<sub>2</sub> *in vitro*


Vasorelaxation of arteries could result in a reduction in blood pressure. SO<sub>2</sub> derivatives (50 to 1000 μM) exerted a concentration-dependent dilatory effect in the aortic rings precontracted



**Fig 3. H<sub>2</sub>S inhibited the vasorelaxation induced by SO<sub>2</sub> *in vitro*.** Rat aortic rings were incubated with vehicle, PPG (100 µmol/L), BCA (100 µmol/L) or NaHS (50 µmol/L) for 10 minutes, then precontracted with PE (3 µmol/L), and finally treated with various concentrations of Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (50–1000 µmol/L). Data are presented as mean±SEM; n = 8 in the SO<sub>2</sub> group, PPG+SO<sub>2</sub> group and NaHS+SO<sub>2</sub> group, and n = 10 in the BCA+SO<sub>2</sub> group; One-way ANOVA followed by LSD post hoc test; \*P<0.05 compared with SO<sub>2</sub> group.

<https://doi.org/10.1371/journal.pone.0264891.g003>

with 3 µmol/L PE (Fig 3). SO<sub>2</sub> derivatives-elicited vasodilation was significantly increased in the aortic rings preincubated with either PPG or BCA but decreased in aortic rings pretreated with NaHS (Fig 3). In addition, there was no significant difference in PE-elicited constriction in aortic rings between SO<sub>2</sub> group and PPG+SO<sub>2</sub> group (Fig 4). These results demonstrate that



**Fig 4. H<sub>2</sub>S did not influence the effect of SO<sub>2</sub> on the phenylephrine (PE)-elicited vasoconstriction.** Rat aortic rings were incubated with Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (1 mmol/L) or PPG (100 µmol/L) plus Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (1 mmol/L), and then treated with various concentrations of PE (0.003–10 µmol/L). Data are presented as mean±SEM; n = 8 in each group; Student's t-test.


<https://doi.org/10.1371/journal.pone.0264891.g004>



H<sub>2</sub>S might inhibit the decrease of vascular tone caused by SO<sub>2</sub> through weakening the SO<sub>2</sub>-induced vasodilation, thus attenuating the transient hypotensive effect of SO<sub>2</sub>.

### NO/eNOS and CO/HO pathway did not change during the regulation of H<sub>2</sub>S on SO<sub>2</sub>

To investigate whether NO and CO are involved in the regulation of H<sub>2</sub>S on SO<sub>2</sub> action, we detected the plasma NO content and the expressions of NO producing enzyme eNOS and CO producing enzymes HO-1 and HO-2 in the rat aortic tissues. The data showed that the plasma NO content (Fig 5A) and the protein expressions of aortic eNOS (Fig 5B), HO-1 (Fig 5C) and HO-2 (Fig 5D) had no significant change at 1.5 minute after SO<sub>2</sub> derivatives injection



**Fig 5. NO/eNOS and CO/HO pathway did not change during the regulation of H<sub>2</sub>S on SO<sub>2</sub>.** Rats were intravenously injected with PPG (30 mg/kg), BCA (50 mg/kg), NaHS (56 µmol/kg) or equal volume of physiological saline. After 30 minutes, the rats were given an intravenous injection of Na<sub>2</sub>SO<sub>3</sub>/NaHSO<sub>3</sub> (40 µmol/kg). Blood samples and aortic tissues were collected after 1.5 minutes. (A) Plasma NO content in each group. (B–D) Representative western blots and quantitative analysis of eNOS (B), HO-1 (C) and HO-2 (D) in the aortic tissues of each group. Data are presented as mean ± SEM; n = 6–7 in each group; One-way ANOVA followed by LSD post hoc test.

<https://doi.org/10.1371/journal.pone.0264891.g005>

compared with the vehicle group. PPG, BCA or NaHS pretreatment for 30 minutes also did not change the effect of SO<sub>2</sub> on these indexes (Fig 5). These results suggest that NO and CO pathway might not be involved in the regulation of H<sub>2</sub>S on SO<sub>2</sub> action.

## Discussion

Our study, for the first time, confirmed that the interaction between H<sub>2</sub>S and SO<sub>2</sub> controls the basal blood pressure and vascular tone *in vivo* and *in vitro*. H<sub>2</sub>S negatively controls the plasma contents of SO<sub>2</sub> and its vasorelaxant effect.

Both H<sub>2</sub>S and SO<sub>2</sub> can be generated endogenously through the metabolic pathway of sulfur-containing amino acids in mammals [2,27–31]. Under certain biochemical conditions, H<sub>2</sub>S and SO<sub>2</sub> can be converted to each other in cells. For example, neutrophils convert H<sub>2</sub>S to SO<sub>2</sub> through oxidative stress [32]. H<sub>2</sub>S is oxidized by sulfide oxidase to generate thiosulfate, which is further converted to SO<sub>2</sub> in the presence of thiosulfate sulfurtransferase [1]. In addition to metabolic pathways, crosstalk between these two gasotransmitters has also been observed in monocrotaline-induced pulmonary hypertensive rat model, where H<sub>2</sub>S was found to inhibit SO<sub>2</sub> generation from lung tissues [18]. However, it was not clear whether there is a possible interaction between H<sub>2</sub>S and SO<sub>2</sub> under physiological conditions. In this study, after the intravenous injection of PPG or BCA to inhibit endogenous H<sub>2</sub>S generation, rat plasma H<sub>2</sub>S levels decreased but SO<sub>2</sub> levels increased. Conversely, injection of H<sub>2</sub>S donor NaHS to upregulate H<sub>2</sub>S levels could downregulate plasma SO<sub>2</sub> contents. These results indicate that H<sub>2</sub>S inhibits the plasma levels of SO<sub>2</sub>, so as to maintain a low concentration of SO<sub>2</sub> under physiological conditions. As for the mechanism by which H<sub>2</sub>S inhibits SO<sub>2</sub> levels, a previous study showed that H<sub>2</sub>S could sulfhydrylate AAT, a key enzyme catalyzing SO<sub>2</sub> generation, to suppress its activity, thus inhibiting endogenous SO<sub>2</sub> production and content [18].

Both H<sub>2</sub>S and SO<sub>2</sub> are important gasotransmitters and play important roles in cardiovascular system [33,34]. Studies have shown that the administration of H<sub>2</sub>S or SO<sub>2</sub> donors antagonizes hypertension in a variety of hypertensive animal models including spontaneously hypertensive rats and angiotensin II-induced hypertensive mice [35–37]. In the present study, MBP of rats was decreased rapidly after the intravenous injection of the SO<sub>2</sub> donor (40 μmol/kg), and then returned to normal levels. This suggests that SO<sub>2</sub> reduces blood pressure under physiological conditions, and this hypotensive effect is rapid and transient. However, the role of H<sub>2</sub>S in the regulation of basal blood pressure by SO<sub>2</sub> is still unclear. In this study, after the intravenous injection of PPG or BCA to inhibit endogenous H<sub>2</sub>S production, the plasma H<sub>2</sub>S level was decreased, the SO<sub>2</sub> level increased, and the hypotensive effect induced by SO<sub>2</sub> was markedly promoted. Conversely, injection of NaHS to increase H<sub>2</sub>S level and decrease SO<sub>2</sub> level could attenuate the hypotensive effect of SO<sub>2</sub>. These results suggest that the interaction between H<sub>2</sub>S and SO<sub>2</sub> is important for the maintenance of physiological blood pressure.

It is known that the vasorelaxant effect of SO<sub>2</sub> is one of the important mechanisms by which this compound exerts antihypertensive effect. The present study also showed that the treatment with SO<sub>2</sub> donor could relax aortic rings. However, the role of H<sub>2</sub>S in the regulation of vascular tension by SO<sub>2</sub> remains unclear. In this study, the pretreatment of aortic rings with PPG or BCA to suppress endogenous H<sub>2</sub>S generation could promote the vasorelaxation of SO<sub>2</sub>. While, pre-incubation of aortic rings with NaHS to increase H<sub>2</sub>S level could attenuate the vasorelaxation of SO<sub>2</sub>. These results suggest that H<sub>2</sub>S negatively controls the vasorelaxant effect of SO<sub>2</sub>. Previous studies have reported that the K<sub>ATP</sub> channel, calcium channel, and cGMP signaling are all involved in the vasorelaxant effect of H<sub>2</sub>S and SO<sub>2</sub> [38–43]. These targets and signaling pathways might be responsible for the biological effects of sulfur-containing gasotransmitter networks. For example, both H<sub>2</sub>S and SO<sub>2</sub> increase cGMP content. Although

H<sub>2</sub>S does not directly activate soluble guanylate cyclase (sGC), it strongly inhibits phosphodiesterase (PDE) 5A to delay cGMP degradation [39]. SO<sub>2</sub> not only promotes the formation of a heterodimer of sGC  $\alpha$  and  $\beta$  subunits to activate sGC and promote cGMP synthesis but also inhibits PDE activity to suppress cGMP degradation, thus increasing the cGMP content [44]. The promotion of these two gasotransmitters at the cGMP level activates PKG signaling and induces vasodilatory effect. However, SO<sub>2</sub> and H<sub>2</sub>S would not work alone, but rather H<sub>2</sub>S controls SO<sub>2</sub> action, which might prevent excessive cGMP production. However, the possible comprehensive effects of the interaction between H<sub>2</sub>S and SO<sub>2</sub> on these targets remain unknown, which merits further studies.


Previous studies showed that SO<sub>2</sub> supplementation for 8 weeks upregulated plasma NO/eNOS pathway in the atherosclerotic rats [5], while H<sub>2</sub>S treatment for 2 h suppressed this pathway in the rat aortic tissues [45]. SO<sub>2</sub> treatment for 24 h elevated the level of HO-1, producer of the gasotransmitter CO, in human skin keratinocytes [46], while blocking H<sub>2</sub>S production with PPG for 1 week induced HO-1 in rats [47]. In the present study, we found that the plasma NO content and the expressions of aortic eNOS, HO-1 and HO-2 had no significant change at 1.5 minute after SO<sub>2</sub> injection. PPG, BCA or NaHS pretreatment for 30 minutes also did not change the effect of SO<sub>2</sub> on these indexes, suggesting that NO and CO pathway might not be involved in the regulation of H<sub>2</sub>S on SO<sub>2</sub> action. Differences under experimental conditions might contribute to the discrepancy between our results and those reported in the literatures.

Although PPG is usually used as an inhibitor of H<sub>2</sub>S production, it is unspecific [48]. It also inhibits other pyridoxal phosphate (PLP) enzymes. In the present study, we also used another CSE inhibitor BCA to inhibit H<sub>2</sub>S production and observed that the effect of PPG could be reproduced. The potential off-target effects of these compounds must be kept in mind when interpreting the data. Therefore, genetic methods are needed to study the complex interaction between H<sub>2</sub>S and SO<sub>2</sub> in the future studies.

The limitation of this study was that the effect of H<sub>2</sub>S on the SO<sub>2</sub>-induced vasodilation was measured in the aorta. Although the change of vascular reactivity of this conductance vessel could be used as an early indicator of the development of diseases related to abnormal blood pressure, the resistance artery is more closely correlated to blood pressure control. Therefore, it is necessary to further confirm the effect of the interaction between H<sub>2</sub>S and SO<sub>2</sub> on vasodilation in arteries such as mesenteric arteries in the future. Factors such as pH, trace metals and oxygen content in buffers, material of measuring container, oxidant of sulfide and reaction of sulfide with many different species (including superoxide radical, hydrogen peroxide and peroxynitrite) were found to affect the determination of H<sub>2</sub>S, resulting in the highly variable absolute H<sub>2</sub>S concentration in biological samples measured by different methods [49]. In fact, measuring H<sub>2</sub>S concentrations is still a matter of debate. There is no unified method for the determination of H<sub>2</sub>S in plasma or tissue samples. Some studies show that plasma sulfide is well below 1  $\mu$ M, and still many studies indicate that the plasma sulfide levels determined by different methods including liquid chromatography-mass spectrometry, methylene blue method, H<sub>2</sub>S-selective sensor and H<sub>2</sub>S-specific fluorescent probes were tens of micromoles [21,49–56], which was consistent with our results. In the future, highly selective, sensitive and accurate H<sub>2</sub>S measurement methods are still needed to improve the unresolved limitations of the current methods.

## Conclusion

Our *in vivo* and *in vitro* findings provide new clues for the integrated regulation of H<sub>2</sub>S and SO<sub>2</sub> to control blood pressure and vascular tension. Our results suggest that H<sub>2</sub>S negatively



**Fig 6.** H<sub>2</sub>S negatively controls the plasma content of SO<sub>2</sub>, its vasorelaxant effect and transient hypotensive response.

<https://doi.org/10.1371/journal.pone.0264891.g006>

controls the plasma content of SO<sub>2</sub>, the vasorelaxant effect and the transient hypotensive response (Fig 6). The findings indicate that SO<sub>2</sub> acts as a compensatory defense gaseous molecule for H<sub>2</sub>S when it is disturbed, playing a vascular protective role. A better understanding of the integrated regulation of these two sulfur-containing gasotransmitters in vascular function would provide new ideas to further explore the pathogenesis of cardiovascular diseases and reveal new targets for their treatment in the future.

## Supporting information

**S1 Fig. The interconversion of SO<sub>3</sub><sup>2-</sup>, HSO<sub>3</sub><sup>-</sup> and SO<sub>2</sub>.**  
(TIF)

**S2 Fig. The effects of pre-administrated PPG, BCA or NaHS on rat blood pressure.**

Changes in mean blood pressure of rats within 1 minute after injected with PPG (30 mg/kg), BCA (50 mg/kg) or NaHS (56 μmol/kg). Data are mean±SEM; n = 8 in each group; Student's t-test; \*P<0.05 compared with zero time point.

(TIF)

**S1 Data. Raw data.**  
(RAR)

## Author Contributions

**Conceptualization:** Yanan Zhang, Junbao Du, Hongfang Jin, Yaqian Huang.

**Data curation:** Chufan Sun, Wen Yu, Boyang lv, Yanan Zhang, Shuxu Du, Heng Zhang, Hongfang Jin, Yan Sun, Yaqian Huang.

**Formal analysis:** Wen Yu, Boyang lv, Yanan Zhang, Shuxu Du, Heng Zhang, Hongfang Jin, Yaqian Huang.

**Funding acquisition:** Hongfang Jin, Yaqian Huang.

**Investigation:** Chufan Sun, Wen Yu, Boyang lv, Yanan Zhang, Shuxu Du, Heng Zhang, Junbao Du, Hongfang Jin, Yan Sun, Yaqian Huang.

**Project administration:** Chufan Sun, Wen Yu, Boyang lv, Yanan Zhang, Shuxu Du, Yan Sun.

**Resources:** Chufan Sun, Wen Yu, Boyang lv, Shuxu Du, Yan Sun.

**Software:** Chufan Sun, Wen Yu, Boyang lv, Yanan Zhang, Shuxu Du, Yan Sun, Yaqian Huang.

**Supervision:** Junbao Du, Hongfang Jin, Yaqian Huang.

**Visualization:** Wen Yu, Boyang lv, Shuxu Du, Junbao Du, Hongfang Jin, Yaqian Huang.

**Writing – original draft:** Chufan Sun, Shuxu Du, Yan Sun, Yaqian Huang.

**Writing – review & editing:** Chufan Sun, Wen Yu, Boyang Lv, Yanan Zhang, Shuxu Du, Heng Zhang, Junbao Du, Hongfang Jin, Yan Sun, Yaqian Huang.

## References

1. Wang W, Wang B. SO<sub>2</sub> donors and prodrugs, and their possible applications: a review. *Front Chem*. 2018; 6:559. Epub 2018/12/07. <https://doi.org/10.3389/fchem.2018.00559> PMID: 30505833; PubMed Central PMCID: MCPMC6250732.
2. Griffith OW. Cysteinesulfinate metabolism. altered partitioning between transamination and decarboxylation following administration of beta-methyleneaspartate. *J Biol Chem*. 1983; 258(3):1591–8. Epub 1983/02/10. PMID: 6822523
3. Du SX, Jin HF, Bu DF, Zhao X, Geng B, Tang CS, et al. Endogenously generated sulfur dioxide and its vasorelaxant effect in rats. *Acta Pharmacol Sin*. 2008; 29(8):923–30. Epub 2008/07/31. <https://doi.org/10.1111/j.1745-7254.2008.00845.x> PMID: 18664325.
4. Day JJ, Yang Z, Chen W, Pacheco A, Xian M. Benzothiazole sulfinate: a water-soluble and slow-releasing sulfur dioxide donor. *ACS Chem Biol*. 2016; 11(6):1647–51. Epub 2016/04/01. <https://doi.org/10.1021/acscchembio.6b00106> PMID: 27031093.
5. Li W, Tang C, Jin H, Du J. Regulatory effects of sulfur dioxide on the development of atherosclerotic lesions and vascular hydrogen sulfide in atherosclerotic rats. *Atherosclerosis*. 2011; 215(2):323–30. Epub 2011/02/09. <https://doi.org/10.1016/j.atherosclerosis.2010.12.037> PMID: 21300352.
6. Luo L, Liu D, Tang C, Du J, Liu AD, Holmberg L, et al. Sulfur dioxide upregulates the inhibited endogenous hydrogen sulfide pathway in rats with pulmonary hypertension induced by high pulmonary blood flow. *Biochem Biophys Res Commun*. 2013; 433(4):519–25. Epub 2013/03/26. <https://doi.org/10.1016/j.bbrc.2013.03.014> PMID: 23524260.
7. Jin H, Wang Y, Wang X, Sun Y, Tang C, Du J. Sulfur dioxide preconditioning increases antioxidative capacity in rat with myocardial ischemia reperfusion (I/R) injury. *Nitric Oxide*. 2013; 32:56–61. Epub 2013/05/01. <https://doi.org/10.1016/j.niox.2013.04.008> PMID: 23629152.
8. Sun HJ, Wu ZY, Nie XW, Bian JS. Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide. *Front Pharmacol*. 2019; 10:1568. Epub 2020/02/11. <https://doi.org/10.3389/fphar.2019.01568> PMID: 32038245; PubMed Central PMCID: MCPMC6985156.
9. Watts M, Kolluru GK, Dherange P, Pardue S, Si M, Shen X, et al. Decreased bioavailability of hydrogen sulfide links vascular endothelium and atrial remodeling in atrial fibrillation. *Redox biology*. 2021; 38:101817. Epub 2020/12/15. <https://doi.org/10.1016/j.redox.2020.101817> PMID: 33310503; PubMed Central PMCID: MCPMC7732878.
10. Szijártó IA, Markó L, Filipovic MR, Miljkovic JL, Tabeling C, Tsvetkov D, et al. Cystathionine  $\gamma$ -Lyase-produced hydrogen sulfide controls endothelial NO bioavailability and blood pressure. *Hypertension*. 2018; 71(6):1210–7. Epub 2018/05/02. <https://doi.org/10.1161/HYPERTENSIONAHA.117.10562> PMID: 29712741.
11. Gadalla MM, Snyder SH. Hydrogen sulfide as a gasotransmitter. *J Neurochem*. 2010; 113(1):14–26. Epub 2010/01/14. <https://doi.org/10.1111/j.1471-4159.2010.06580.x> PMID: 20067586; PubMed Central PMCID: MCPMC2965526.
12. Mitidieri E, Tramontano T, Gurgone D, Citi V, Calderone V, Brancaleone V, et al. Mercaptopyruvate acts as endogenous vasodilator independently of 3-mercaptopyruvate sulfurtransferase activity. *Nitric Oxide*. 2018; 75:53–9. Epub 2018/02/17. <https://doi.org/10.1016/j.niox.2018.02.003> PMID: 29452248.
13. Gheibi S, Jeddi S, Kashfi K, Ghasemi A. Regulation of vascular tone homeostasis by NO and H(2)S: Implications in hypertension. *Biochem Pharmacol*. 2018; 149:42–59. Epub 2018/01/14. <https://doi.org/10.1016/j.bcp.2018.01.017> PMID: 29330066; PubMed Central PMCID: MCPMC5866223.
14. Kanagy NL, Szabo C, Papapetropoulos A. Vascular biology of hydrogen sulfide. *Am J Physiol Cell Physiol*. 2017; 312(5):C537–c49. Epub 2017/02/06. <https://doi.org/10.1152/ajpcell.00329.2016> PMID: 28148499; PubMed Central PMCID: MCPMC5451519.
15. Rajendran S, Shen X, Glawe J, Kolluru GK, Kevil CG. Nitric oxide and hydrogen sulfide regulation of ischemic vascular growth and remodeling. *Comprehensive Physiology*. 2019; 9(3):1213–47. Epub 2019/06/13. <https://doi.org/10.1002/cphy.c180026> PMID: 31187898; PubMed Central PMCID: MCPMC6938731.
16. Cirino G, Vellecco V, Bucci M. Nitric oxide and hydrogen sulfide: the gasotransmitter paradigm of the vascular system. *Br J Pharmacol*. 2017; 174(22):4021–31. Epub 2017/04/14. <https://doi.org/10.1111/bph.13815> PMID: 28407204; PubMed Central PMCID: MCPMC5660007.

17. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, et al. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. *Circ Res*. 2009; 105(4):365–74. Epub 2009/07/18. <https://doi.org/10.1161/CIRCRESAHA.109.199919> PMID: 19608979; PubMed Central PMCID: MCPMC2735849.
18. Zhang D, Wang X, Tian X, Zhang L, Yang G, Tao Y, et al. The increased endogenous sulfur dioxide acts as a compensatory mechanism for the downregulated endogenous hydrogen sulfide pathway in the endothelial cell inflammation. *Front Immunol*. 2018; 9:882. Epub 2018/05/16. <https://doi.org/10.3389/fimmu.2018.00882> PMID: 29760703; PubMed Central PMCID: MCPMC5936987.
19. Meyer B. Industrial uses of sulfur and its compounds. *Sulfur, Energy, and Environment*. 1977:279–90.
20. Beauchamp RO, Jr., Bus JS, Popp JA, Boreiko CJ, Andjelkovich DA. A critical review of the literature on hydrogen sulfide toxicity. *Crit Rev Toxicol*. 1984; 13(1):25–97. Epub 1984/01/01. <https://doi.org/10.3109/10408448409029321> PMID: 6378532.
21. Ahmad A, Druzhyna N, Szabo C. Delayed treatment with sodium hydrosulfide improves regional blood flow and alleviates cecal ligation and puncture (CLP)-induced septic shock. *Shock*. 2016; 46(2):183–93. Epub 2016/02/11. <https://doi.org/10.1097/SHK.0000000000000589> PMID: 26863032; PubMed Central PMCID: MCPMC4949092.
22. Lu HY, Hsu HL, Li CH, Li SJ, Lin SJ, Shih CM, et al. Hydrogen sulfide attenuates aortic remodeling in aortic dissection associating with moderated inflammation and oxidative stress through a NO-dependent pathway. *Antioxidants (Basel, Switzerland)*. 2021; 10(5). Epub 2021/05/01. <https://doi.org/10.3390/antiox10050814> PMID: 34065248; PubMed Central PMCID: MCPMC8145450.
23. Han Y, Yi W, Qin J, Zhao Y, Zhang J, Chang X. Dose-dependent effect of sulfur dioxide on brain damage induced by recurrent febrile seizures in rats. *Neurosci Lett*. 2014; 563:149–54. Epub 2014/01/01. <https://doi.org/10.1016/j.neulet.2013.12.042> PMID: 24373994.
24. Wang XB, Huang XM, Ochs T, Li XY, Jin HF, Tang CS, et al. Effect of sulfur dioxide preconditioning on rat myocardial ischemia/reperfusion injury by inducing endoplasmic reticulum stress. *Basic Res Cardiol*. 2011; 106(5):865–78. Epub 2011/04/07. <https://doi.org/10.1007/s00395-011-0176-x> PMID: 21468766.
25. Zhong G, Chen F, Cheng Y, Tang C, Du J. The role of hydrogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase. *J Hypertens*. 2003; 21(10):1879–85. Epub 2003/09/26. <https://doi.org/10.1097/00004872-200310000-00015> PMID: 14508194.
26. Zhang D, Wang X, Chen S, Chen S, Yu W, Liu X, et al. Endogenous hydrogen sulfide sulfhydrates IKK $\beta$  at cysteine 179 to control pulmonary artery endothelial cell inflammation. *Clin Sci (Lond)*. 2019; 133(20):2045–59. Epub 2019/10/28. <https://doi.org/10.1042/CS20190514> PMID: 31654061.
27. Recasens M, Benezra R, Basset P, Mandel P. Cysteine sulfinatase aminotransferase and aspartate aminotransferase isoenzymes of rat brain. Purification, characterization, and further evidence for identity. *Biochemistry*. 1980; 19(20):4583–9. Epub 1980/09/30. <https://doi.org/10.1021/bi00561a007> PMID: 7426616.
28. Kožich V, Stabler S. Lessons Learned from Inherited Metabolic Disorders of Sulfur-Containing Amino Acids Metabolism. *J Nutr*. 2020; 150(Suppl 1):2506s–17s. Epub 2020/10/02. <https://doi.org/10.1093/jn/nxaa134> PMID: 33000152.
29. Olas B. Hydrogen sulfide in signaling pathways. *Clin Chim Acta*. 2015; 439:212–8. Epub 2014/12/03. <https://doi.org/10.1016/j.cca.2014.10.037> PMID: 25444740.
30. Szabo C, Papapetropoulos A. International union of basic and clinical pharmacology. CII: pharmacological modulation of H(2)S levels: H(2)S donors and H(2)S biosynthesis inhibitors. *Pharmacol Rev*. 2017; 69(4):497–564. Epub 2017/10/06. <https://doi.org/10.1124/pr.117.014050> PMID: 28978633; PubMed Central PMCID: MCPMC5629631.
31. Rose P, Moore PK, Zhu YZ. H(2)S biosynthesis and catabolism: new insights from molecular studies. *Cell Mol Life Sci*. 2017; 74(8):1391–412. Epub 2016/11/16. <https://doi.org/10.1007/s00018-016-2406-8> PMID: 27844098; PubMed Central PMCID: MCPMC5357297.
32. Mitsuhashi H, Yamashita S, Ikeuchi H, Kuroiwa T, Kaneko Y, Hiromura K, et al. Oxidative stress-dependent conversion of hydrogen sulfide to sulfite by activated neutrophils. *Shock*. 2005; 24(6):529–34. Epub 2005/12/01. <https://doi.org/10.1097/01.shk.0000183393.83272.de> PMID: 16317383.
33. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, et al. H<sub>2</sub>S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. *Science*. 2008; 322(5901):587–90. Epub 2008/10/25. <https://doi.org/10.1126/science.1162667> PMID: 18948540; PubMed Central PMCID: MCPMC2749494.
34. Jin HF, Du SX, Zhao X, Wei HL, Wang YF, Liang YF, et al. Effects of endogenous sulfur dioxide on monocrotaline-induced pulmonary hypertension in rats. *Acta Pharmacol Sin*. 2008; 29(10):1157–66. Epub 2008/09/27. <https://doi.org/10.1111/j.1745-7254.2008.00864.x> PMID: 18817619.

35. Sun Y, Huang Y, Zhang R, Chen Q, Chen J, Zong Y, et al. Hydrogen sulfide upregulates KATP channel expression in vascular smooth muscle cells of spontaneously hypertensive rats. *J Mol Med (Berl)*. 2015; 93(4):439–55. Epub 2014/11/22. <https://doi.org/10.1007/s00109-014-1227-1> PMID: 25412775.
36. Chi Z, Byeon HE, Seo E, Nguyen QT, Lee W, Jeong Y, et al. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine  $\gamma$ -lyase protein degradation. *Pharmacol Res*. 2019; 146:104281. Epub 2019/05/28. <https://doi.org/10.1016/j.phrs.2019.104281> PMID: 31125601.
37. Li J, Teng X, Jin S, Dong J, Guo Q, Tian D, et al. Hydrogen sulfide improves endothelial dysfunction by inhibiting the vicious cycle of NLRP3 inflammasome and oxidative stress in spontaneously hypertensive rats. *J Hypertens*. 2019; 37(8):1633–43. Epub 2019/05/07. <https://doi.org/10.1097/HJH.0000000000002101> PMID: 31058793.
38. Huang Y, Tang C, Du J, Jin H. Endogenous sulfur dioxide: a new member of gasotransmitter family in the cardiovascular system. *Oxid Med Cell Longev*. 2016; 2016:8961951. Epub 2016/02/04. <https://doi.org/10.1155/2016/8961951> PMID: 26839635; PubMed Central PMCID: MCPMC4709694.
39. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Zaid A, Giannogonas P, et al. cGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation. *PLoS One*. 2012; 7(12):e53319. Epub 2013/01/04. <https://doi.org/10.1371/journal.pone.0053319> PMID: 23285278; PubMed Central PMCID: MCPMC3532056.
40. Dunn WR, Alexander SP, Ralevic V, Roberts RE. Effects of hydrogen sulphide in smooth muscle. *Pharmacol Ther*. 2016; 158:101–13. Epub 2015/12/27. <https://doi.org/10.1016/j.pharmthera.2015.12.007> PMID: 26706238.
41. Nagpure BV, Bian JS. Interaction of hydrogen sulfide with nitric oxide in the cardiovascular system. *Oxid Med Cell Longev*. 2016; 2016:6904327. Epub 2015/12/08. <https://doi.org/10.1155/2016/6904327> PMID: 26640616; PubMed Central PMCID: MCPMC4657111.
42. Bibli SI, Yang G, Zhou Z, Wang R, Topouzis S, Papapetropoulos A. Role of cGMP in hydrogen sulfide signaling. *Nitric Oxide*. 2015; 46:7–13. Epub 2015/01/03. <https://doi.org/10.1016/j.niox.2014.12.004> PMID: 25553675.
43. Cao X, Wu Z, Xiong S, Cao L, Sethi G, Bian JS. The role of hydrogen sulfide in cyclic nucleotide signaling. *Biochem Pharmacol*. 2018; 149:20–8. Epub 2017/11/22. <https://doi.org/10.1016/j.bcp.2017.11.011> PMID: 29158149.
44. Yao Q, Huang Y, Liu AD, Zhu M, Liu J, Yan H, et al. The vasodilatory effect of sulfur dioxide via SGC/cGMP/PKG pathway in association with sulfhydryl-dependent dimerization. *Am J Physiol Regul Integr Comp Physiol*. 2016; 310(11):R1073–80. Epub 2016/03/25. <https://doi.org/10.1152/ajpregu.00101.2015> PMID: 27009048.
45. Geng B, Cui Y, Zhao J, Yu F, Zhu Y, Xu G, et al. Hydrogen sulfide downregulates the aortic L-arginine/nitric oxide pathway in rats. *Am J Physiol Regul Integr Comp Physiol*. 2007; 293(4):R1608–18. Epub 2007/07/20. <https://doi.org/10.1152/ajpregu.00207.2006> PMID: 17634203.
46. Liang J, Liu L, Kang X, Hu F, Mao L. Mechanism underlying the effect of SO<sub>2</sub>-induced oxidation on human skin keratinocytes. *Medicine (Baltimore)*. 2020; 99(48):e23152. Epub 2020/11/26. <https://doi.org/10.1097/MD.00000000000023152> PMID: 33235076; PubMed Central PMCID: MCPMC7710201.
47. Oosterhuis NR, Frenay AR, Wesseling S, Snijder PM, Slaats GG, Yazdani S, et al. DL-propargylglycine reduces blood pressure and renal injury but increases kidney weight in angiotensin-II infused rats. *Nitric Oxide*. 2015; 49:56–66. Epub 2015/07/21. <https://doi.org/10.1016/j.niox.2015.07.001> PMID: 26192363.
48. Köhn C, Schleifenbaum J, Szijártó IA, Markó L, Dubrovská G, Huang Y, et al. Differential effects of cystathionine- $\gamma$ -lyase-dependent vasodilatory H<sub>2</sub>S in periaortic vasoregulation of rat and mouse aortas. *PLoS One*. 2012; 7(8):e41951. Epub 2012/08/08. <https://doi.org/10.1371/journal.pone.0041951> PMID: 22870268; PubMed Central PMCID: MCPMC3411702.
49. Shen X, Pattillo CB, Pardue S, Bir SC, Wang R, Kevil CG. Measurement of plasma hydrogen sulfide in vivo and in vitro. *Free Radic Biol Med*. 2011; 50(9):1021–31. Epub 2011/02/01. <https://doi.org/10.1016/j.freeradbiomed.2011.01.025> PMID: 21276849; PubMed Central PMCID: MCPMC4798232.
50. Zhu ML, Zhao FR, Zhu TT, Wang QQ, Wu ZQ, Song P, et al. The antihypertension effect of hydrogen sulfide (H<sub>2</sub>S) is induced by activating VEGFR2 signaling pathway. *Life Sci*. 2021; 267:118831. Epub 2020/12/01. <https://doi.org/10.1016/j.lfs.2020.118831> PMID: 33253721.
51. Liu Y, Wei Z, Zhou J, Ma Z. Simultaneous multi-signal quantification for highly precise serodiagnosis utilizing a rationally constructed platform. *Nature communications*. 2019; 10(1):5361. Epub 2019/11/27. <https://doi.org/10.1038/s41467-019-13358-0> PMID: 31767865; PubMed Central PMCID: MCPMC6877524.
52. Alyan AK, Hanafi RS, Gad MZ. Point-of-care testing and optimization of sample treatment for fluorometric determination of hydrogen sulphide in plasma of cardiovascular patients. *Journal of advanced*

- research. 2021; 27:1–10. Epub 2020/12/16. <https://doi.org/10.1016/j.jare.2019.11.010> PMID: 33318861; PubMed Central PMCID: MCPMC7728603.
53. Yuan YQ, Wang YL, Yuan BS, Yuan X, Hou XO, Bian JS, et al. Impaired CBS-H(2)S signaling axis contributes to MPTP-induced neurodegeneration in a mouse model of Parkinson's disease. *Brain Behav Immun*. 2018; 67:77–90. Epub 2017/08/05. <https://doi.org/10.1016/j.bbi.2017.07.159> PMID: 28774789.
  54. Possomato-Vieira JS, Gonçalves-Rizzi VH, do Nascimento RA, Wandekin RR, Caldeira-Dias M, Chimini JS, et al. Clinical and experimental evidences of hydrogen sulfide involvement in lead-induced hypertension. *BioMed research international*. 2018; 2018:4627391. Epub 2018/05/24. <https://doi.org/10.1155/2018/4627391> PMID: 29789795; PubMed Central PMCID: MCPMC5896357.
  55. Coletta C, Módis K, Szczesny B, Brunyánszki A, Oláh G, Rios EC, et al. Regulation of vascular tone, angiogenesis and cellular bioenergetics by the 3-mercaptopyruvate sulfurtransferase/H<sub>2</sub>S pathway: functional impairment by hyperglycemia and restoration by DL- $\alpha$ -lipoic acid. *Mol Med*. 2015; 21(1):1–14. Epub 2015/02/26. <https://doi.org/10.2119/molmed.2015.00035> PMID: 25715337; PubMed Central PMCID: MCPMC4461574.
  56. Wang K, Ahmad S, Cai M, Rennie J, Fujisawa T, Crispi F, et al. Dysregulation of hydrogen sulfide producing enzyme cystathionine  $\gamma$ -lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. *Circulation*. 2013; 127(25):2514–22. Epub 2013/05/25. <https://doi.org/10.1161/CIRCULATIONAHA.113.001631> PMID: 23704251.